CN104203232A - 用于抗肿瘤试剂施用的方法 - Google Patents

用于抗肿瘤试剂施用的方法 Download PDF

Info

Publication number
CN104203232A
CN104203232A CN201380015189.5A CN201380015189A CN104203232A CN 104203232 A CN104203232 A CN 104203232A CN 201380015189 A CN201380015189 A CN 201380015189A CN 104203232 A CN104203232 A CN 104203232A
Authority
CN
China
Prior art keywords
days
day
treatment
drug products
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201380015189.5A
Other languages
English (en)
Chinese (zh)
Inventor
K.格伦
B.希金斯
G.尼科尔斯
K.E.帕克曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Priority to CN201910030832.0A priority Critical patent/CN110013478A/zh
Publication of CN104203232A publication Critical patent/CN104203232A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
CN201380015189.5A 2012-03-19 2013-03-15 用于抗肿瘤试剂施用的方法 Pending CN104203232A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201910030832.0A CN110013478A (zh) 2012-03-19 2013-03-15 用于抗肿瘤试剂施用的方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261612429P 2012-03-19 2012-03-19
US61/612,429 2012-03-19
PCT/EP2013/055324 WO2013139687A1 (en) 2012-03-19 2013-03-15 Method for administration of an anti tumor agent

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201910030832.0A Division CN110013478A (zh) 2012-03-19 2013-03-15 用于抗肿瘤试剂施用的方法

Publications (1)

Publication Number Publication Date
CN104203232A true CN104203232A (zh) 2014-12-10

Family

ID=47913395

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201380015189.5A Pending CN104203232A (zh) 2012-03-19 2013-03-15 用于抗肿瘤试剂施用的方法
CN201910030832.0A Pending CN110013478A (zh) 2012-03-19 2013-03-15 用于抗肿瘤试剂施用的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201910030832.0A Pending CN110013478A (zh) 2012-03-19 2013-03-15 用于抗肿瘤试剂施用的方法

Country Status (21)

Country Link
US (4) US20130245089A1 (https=)
EP (1) EP2827858B1 (https=)
JP (2) JP6224690B2 (https=)
KR (4) KR102438597B1 (https=)
CN (2) CN104203232A (https=)
BR (1) BR112014018135A8 (https=)
CA (1) CA2859940C (https=)
CY (1) CY1118070T1 (https=)
DK (1) DK2827858T3 (https=)
ES (1) ES2593066T3 (https=)
HK (1) HK1204934A1 (https=)
HR (1) HRP20161295T1 (https=)
HU (1) HUE029933T2 (https=)
LT (1) LT2827858T (https=)
MX (1) MX356948B (https=)
PL (1) PL2827858T3 (https=)
PT (1) PT2827858T (https=)
RS (1) RS55250B1 (https=)
RU (1) RU2638795C2 (https=)
SI (1) SI2827858T1 (https=)
WO (1) WO2013139687A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112353762A (zh) * 2013-01-22 2021-02-12 霍夫曼-拉罗奇有限公司 具有改善的生物利用度的药物组合物
EP3459933B1 (en) 2014-04-15 2022-08-24 F. Hoffmann-La Roche AG Solid forms of a pharmaceutically active compound
TW201613576A (en) 2014-06-26 2016-04-16 Novartis Ag Intermittent dosing of MDM2 inhibitor
EP3204776B1 (en) * 2014-10-10 2019-09-04 F.Hoffmann-La Roche Ag Methods for personalizing patient cancer therapy with an mdm2 antagonist
AU2017246452C1 (en) 2016-04-06 2021-06-03 The Regents Of The University Of Michigan MDM2 protein degraders
MX388093B (es) 2016-11-15 2025-03-19 Novartis Ag Dosis y regimen para inhibidores de la interaccion hdm2-p53.
US20210122831A1 (en) 2017-03-27 2021-04-29 Noile-Immune Biotech, Inc. Chimeric antigen receptor
CA3052543A1 (en) 2017-03-31 2018-10-04 Novartis Ag Dose and regimen for an hdm2-p53 interaction inhibitor in hematological tumors
TWI791794B (zh) 2018-03-20 2023-02-11 瑞士商諾華公司 藥物組合
MX2021007391A (es) 2018-12-20 2021-09-23 Novartis Ag Regimenes de baja dosis extendida para inhibidores de mdm2.

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100152190A1 (en) * 2008-09-18 2010-06-17 David Joseph Bartkovitz Substituted Pyrrolidine-2-Carboxamides

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101595107A (zh) * 2006-06-30 2009-12-02 先灵公司 能提高p53活性的有取代哌啶及其用途
WO2008076415A1 (en) 2006-12-14 2008-06-26 Exelixis, Inc. Methods of using mek inhibitors
US20120010235A1 (en) * 2010-07-12 2012-01-12 Xin-Jie Chu N-substituted pyrrolidines
US9216170B2 (en) 2012-03-19 2015-12-22 Hoffmann-La Roche Inc. Combination therapy for proliferative disorders

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100152190A1 (en) * 2008-09-18 2010-06-17 David Joseph Bartkovitz Substituted Pyrrolidine-2-Carboxamides

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HEGE O OHNSTAD ET AL: "MDM2 antagonist Nutlin-3a potentiates antitumour activity of cytotoxic drugs in sarcoma cell lines", 《BMC CANCER》 *
JA CANNER ET AL: "MI-63: A novel small-molecule inhibitor targets MDM2 and induces apoptosis in embryonal and alveolar rhabdomyosarcoma cells with wild-type p53", 《BRITISH JOURNAL OF CANCER》 *

Also Published As

Publication number Publication date
CY1118070T1 (el) 2017-06-28
ES2593066T3 (es) 2016-12-05
EP2827858A1 (en) 2015-01-28
JP6224690B2 (ja) 2017-11-01
EP2827858B1 (en) 2016-07-20
BR112014018135A2 (https=) 2017-06-20
KR20210016073A (ko) 2021-02-10
KR102438597B1 (ko) 2022-08-31
US20190328708A1 (en) 2019-10-31
PT2827858T (pt) 2016-09-23
MX2014010586A (es) 2014-09-18
DK2827858T3 (en) 2016-08-22
JP2015510906A (ja) 2015-04-13
HRP20161295T1 (hr) 2016-11-18
US11738003B2 (en) 2023-08-29
BR112014018135A8 (pt) 2021-10-19
HK1204934A1 (en) 2015-12-11
HUE029933T2 (en) 2017-04-28
WO2013139687A1 (en) 2013-09-26
KR20190035957A (ko) 2019-04-03
JP2017061461A (ja) 2017-03-30
PL2827858T3 (pl) 2017-01-31
RU2638795C2 (ru) 2017-12-15
LT2827858T (lt) 2016-10-10
CN110013478A (zh) 2019-07-16
KR20140133583A (ko) 2014-11-19
RS55250B1 (sr) 2017-02-28
RU2014141365A (ru) 2016-05-10
MX356948B (es) 2018-06-20
KR20160089549A (ko) 2016-07-27
US20210069149A1 (en) 2021-03-11
SI2827858T1 (sl) 2016-11-30
US20150126575A1 (en) 2015-05-07
CA2859940C (en) 2020-03-24
US20130245089A1 (en) 2013-09-19
CA2859940A1 (en) 2013-09-26

Similar Documents

Publication Publication Date Title
US11738003B2 (en) Method for administration
RU2757373C2 (ru) Комбинированная терапия противоопухолевым алкалоидом
JP6141958B2 (ja) 増殖性疾患の治療のための併用療法（ベムラフェニブ及びｍｄｍ２阻害剤）
WO2020170164A1 (en) Treating gastric cancer using ttfields combined with xelox or folfox
ES2535000T3 (es) Composiciones para el tratamiento de cáncer
ES3036485T3 (en) Combination comprising everolimus and amcenestrant
JP2014513705A (ja) 進行性固形腫瘍の治療方法
CA2919731A1 (en) Combinations of a btk inhibitor and fluorouracil for treating cancers
RU2678103C2 (ru) Противоопухолевое средство, содержащее противоопухолевый комплекс платины, и усилитель противоопухолевого эффекта
TW201834650A (zh) 哺乳類雷帕黴素靶蛋白抑制劑及氯喹於治療癌症之用途
US11382892B2 (en) Method for administration
HK40011479A (en) Method for administration of an anti-tumor agent
TW201313225A (zh) 與放射線治療關聯之包含奧瑞布林（ｏｍｂｒａｂｕｌｉｎ）及順鉑（ｃｉｓｐｌａｔｉｎ）之抗腫瘤組合

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1204934

Country of ref document: HK

CB02 Change of applicant information

Address after: Basel

Applicant after: Hoffmann La Roche

Address before: Basel

Applicant before: F. Hoffmann-La Roche AG

CB02 Change of applicant information
RJ01 Rejection of invention patent application after publication

Application publication date: 20141210

RJ01 Rejection of invention patent application after publication